Author Manuscript Published OnlineFirst on January 18, 2015; DOI: 10.1158/1055-9965.EPI-13-1281 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Resubmitted to “Cancer Epidemiology, Biomarkers & Prevention” December 10, 2014 Short Communication
Serum YKL-40 in risk assessment for colorectal cancer: A prospective study of 4496 subjects at risk of colorectal cancer
Julia S. Johansen1,2,3, Ib J. Christensen4,5, Lars N. Jørgensen6, Jesper Olsen7, Hans B. Rahr8, Knud T. Nielsen9, Søren Laurberg10, Nils Brünner11, Hans Jørgen Nielsen1,12.
1
Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen;
Departments of 2Oncology and 3Medicine, Copenhagen University Hospital at Herlev; 4The Finsen Laboratory, Rigshospitalet, Copenhagen; University of Copenhagen;
6
5
Biotech Research and Innovation Centre (BRIC),
Department of Surgical Gastroenterology, Bispebjerg Hospital,
Copenhagen; 7Department of Surgery, Glostrup Hospital, Glostrup; 8Department of Surgical Gastroenterology, Odense University Hospital, Odense; 9Department of Surgery, Randers Hospital, Randers;
10
Department of Surgery, Aarhus University Hospital, Aarhus;
Biology Section, University of Copenhagen; and
12
11
Molecular Disease
Department of Surgical Gastroenterology,
Hvidovre Hospital, Hvidovre, Denmark.
Correspondence to: Professor Julia S. Johansen, MD, DMSc, Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2750 Herlev, Denmark. E-mail: [email protected]; Telephone: 45-38689241. Running title: Serum YKL-40 and risk of colorectal cancer Word count: 247 (abstract); 2656 (text). Two tables and one figure. 25 references. Key words: Biomarkers; CHI3L1; Colorectal cancer; YKL-40. Disclosure of Potential Conflicts of Interest: None. 1
Downloaded from cebp.aacrjournals.org on March 20, 2015. © 2015 American Association for Cancer Research.
Author Manuscript Published OnlineFirst on January 18, 2015; DOI: 10.1158/1055-9965.EPI-13-1281 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Grant Support This work was supported by grants from The Danish Cancer Society (HJ Nielsen), The Kornerup Fund (HJ Nielsen), The Aase and Ejnar Danielsen Fund (HJ Nielsen), The Aage and Johanne Louis-Hansen Fund (HJ Nielsen), The Kathrine and Vigo Skovgaard Fund (HJ Nielsen), The HFoundation (HJ Nielsen), The IMK Fund (HJ Nielsen), The Arvid Nilsson Fund (HJ Nielsen), Chief Physician Johan Boserup and Lise Boserups Foundation (JS Johansen) and Toyota-Fonden, Denmark (JS Johansen). Quidel provided the study with some of the YKL-40 ELISA kits (JS Johansen). The study sponsors had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. The authors had full access to all the data in the study and had the final responsibility for the decision to submit the manuscript for publication.
2
Downloaded from cebp.aacrjournals.org on March 20, 2015. © 2015 American Association for Cancer Research.
Author Manuscript Published OnlineFirst on January 18, 2015; DOI: 10.1158/1055-9965.EPI-13-1281 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Abstract The aim of the present study was to test the hypothesis that high serum YKL-40 associates with colorectal cancer (CRC) in subjects at risk of CRC. We measured serum YKL-40 in a prospective study of 4496 Danish subjects (2064 men, 2432 women, median age 61 years (range 18-97)) referred to endoscopy due to symptoms or other risk factors for CRC. Blood samples were collected just before large bowel endoscopy. Serum YKL-40 was determined by ELISA. Serum YKL-40 was higher (p
Resubmitted to “Cancer Epidemiology, Biomarkers & Prevention” December 10, 2014 Short Communication
Serum YKL-40 in risk assessment for colorectal cancer: A prospective study of 4496 subjects at risk of colorectal cancer
Julia S. Johansen1,2,3, Ib J. Christensen4,5, Lars N. Jørgensen6, Jesper Olsen7, Hans B. Rahr8, Knud T. Nielsen9, Søren Laurberg10, Nils Brünner11, Hans Jørgen Nielsen1,12.
1
Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen;
Departments of 2Oncology and 3Medicine, Copenhagen University Hospital at Herlev; 4The Finsen Laboratory, Rigshospitalet, Copenhagen; University of Copenhagen;
6
5
Biotech Research and Innovation Centre (BRIC),
Department of Surgical Gastroenterology, Bispebjerg Hospital,
Copenhagen; 7Department of Surgery, Glostrup Hospital, Glostrup; 8Department of Surgical Gastroenterology, Odense University Hospital, Odense; 9Department of Surgery, Randers Hospital, Randers;
10
Department of Surgery, Aarhus University Hospital, Aarhus;
Biology Section, University of Copenhagen; and
12
11
Molecular Disease
Department of Surgical Gastroenterology,
Hvidovre Hospital, Hvidovre, Denmark.
Correspondence to: Professor Julia S. Johansen, MD, DMSc, Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2750 Herlev, Denmark. E-mail: [email protected]; Telephone: 45-38689241. Running title: Serum YKL-40 and risk of colorectal cancer Word count: 247 (abstract); 2656 (text). Two tables and one figure. 25 references. Key words: Biomarkers; CHI3L1; Colorectal cancer; YKL-40. Disclosure of Potential Conflicts of Interest: None. 1
Downloaded from cebp.aacrjournals.org on March 20, 2015. © 2015 American Association for Cancer Research.
Author Manuscript Published OnlineFirst on January 18, 2015; DOI: 10.1158/1055-9965.EPI-13-1281 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Grant Support This work was supported by grants from The Danish Cancer Society (HJ Nielsen), The Kornerup Fund (HJ Nielsen), The Aase and Ejnar Danielsen Fund (HJ Nielsen), The Aage and Johanne Louis-Hansen Fund (HJ Nielsen), The Kathrine and Vigo Skovgaard Fund (HJ Nielsen), The HFoundation (HJ Nielsen), The IMK Fund (HJ Nielsen), The Arvid Nilsson Fund (HJ Nielsen), Chief Physician Johan Boserup and Lise Boserups Foundation (JS Johansen) and Toyota-Fonden, Denmark (JS Johansen). Quidel provided the study with some of the YKL-40 ELISA kits (JS Johansen). The study sponsors had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. The authors had full access to all the data in the study and had the final responsibility for the decision to submit the manuscript for publication.
2
Downloaded from cebp.aacrjournals.org on March 20, 2015. © 2015 American Association for Cancer Research.
Author Manuscript Published OnlineFirst on January 18, 2015; DOI: 10.1158/1055-9965.EPI-13-1281 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Abstract The aim of the present study was to test the hypothesis that high serum YKL-40 associates with colorectal cancer (CRC) in subjects at risk of CRC. We measured serum YKL-40 in a prospective study of 4496 Danish subjects (2064 men, 2432 women, median age 61 years (range 18-97)) referred to endoscopy due to symptoms or other risk factors for CRC. Blood samples were collected just before large bowel endoscopy. Serum YKL-40 was determined by ELISA. Serum YKL-40 was higher (p
